These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18574020)

  • 1. New antiplatelet therapies in development.
    Price MJ
    Am J Health Syst Pharm; 2008 Jul; 65(13 Suppl 5):S11-5; quiz S16-8. PubMed ID: 18574020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Status of Antiplatelet Therapy in Acute Coronary Syndrome.
    Dash D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):40-9. PubMed ID: 26245659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antiplatelet strategies in acute coronary syndromes.
    Sabatine MS
    Cleve Clin J Med; 2009 Apr; 76 Suppl 1():S8-15. PubMed ID: 19332592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
    Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
    Gunarathne A; Hussain S; Gershlick AH
    Expert Rev Cardiovasc Ther; 2016 Nov; 14(11):1215-1226. PubMed ID: 27701930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The state of periprocedural antiplatelet therapy after recent trials.
    Desai NR; Bhatt DL
    JACC Cardiovasc Interv; 2010 Jun; 3(6):571-83. PubMed ID: 20630450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor: a novel reversible oral antiplatelet agent.
    Nawarskas JJ; Clark SM
    Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prasugrel for arterial coronary thrombosis.
    Serebruany V; Makarov L
    Drugs Today (Barc); 2009 Feb; 45(2):83-91. PubMed ID: 19343228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.
    Coccheri S
    Drugs; 2010 May; 70(7):887-908. PubMed ID: 20426498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prasugrel versus clopidogrel: new management strategies for acute coronary syndrome.
    Schnapf AJ
    J Cardiovasc Nurs; 2013; 28(5):483-94. PubMed ID: 22990232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.